European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
HIFU is a state-of-the-art treatment that utilizes high-frequency sound waves to target and destroy prostate cancer cells
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated
